Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544882 | 0.85 | ALDH1A1 (0.54) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL15330964 | 0.85 | ALDH1A1 (0.56) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL20798229 | 0.85 | MAPT (0.74) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1714052 | 0.84 | PTGDR2 (0.68) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8121860 | 0.84 | KDM4E (0.67) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2559901 | 0.83 | ALDH1A1 (0.56) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2554750 | 0.83 | ALDH1A1 (0.57) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| 2,4-Dichlorophenoxyacetic Acid, Methyl Ester SCHEMBL5004223 | 0.83 | MAPT (0.70) | MAPTALDH1A1MEN1KMT2APTGDR2 | |
| SCHEMBL8782927 | 0.82 | ALDH1A1 (0.64) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2560314 | 0.82 | SMN1; SMN2 (0.71) | MAPTALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421866-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2235017-B1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-09-14 | — | — | EP | disclosed |
| EP-2235017-B1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010121995-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| US-3968117-A | CARDIOVASCULAR | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-06 | — | — | US | disclosed |
| US-3959296-A | CARDIOVASCULAR AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NR3C2, MRGPRX2, HRH2 | MAPT 4232/4885ALDH1A1 1631/4885KDM4E 3892/4885 |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | MAPT 4581/4885ALDH1A1 156/4885KDM4E 2117/4885 |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | SIK3, RB1, CCND3 | MAPT 4554/4885ALDH1A1 1228/4885KDM4E 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.